Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 1Leukemia 1

Interventions

3-Iodobenzylguanidine 3talquetamab 2ibrutinib 2zanubrutinib 1vorasidenib 1sugemalimab 1revumenib 1pomalidomide 1loncastuximab tesirine 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Whole-Body Irradiation 1Tacrolimus 1Panobinostat 1Mycophenolic Acid 1Immunotherapy, Adoptive 1Cytarabine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Recurrence × revumenib × Clear all
NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available
1 FDA
Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡